Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/3/2025 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/22/2023 | $8.00 | Equal-Weight | Morgan Stanley |
| 3/16/2023 | $17.00 | Buy | Needham |
| 9/16/2022 | $20.00 | Overweight | KeyBanc Capital Markets |
| 4/18/2022 | $10.00 | Buy → Neutral | BofA Securities |
| 3/4/2022 | $32.00 → $10.00 | Outperform → Market Perform | SVB Leerink |
| 12/8/2021 | $30.00 → $32.00 | Outperform | SVB Leerink |
| 9/21/2021 | $37.00 | Buy | Berenberg |
Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00
Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00
Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB:AVAI), Tempus Ai, Inc. (NASDAQ:TEM), OmniAb, Inc. (NASDAQ:OABI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Recursion Pharmaceutic
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks The development of this open source model for academic and commercial use was a collaborative effort, combining MIT's deep academic expertise with Recursion's AI research and NVIDIA-accelerated supercomputer, BioHive-2 Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
424B7 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first
Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the
SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta
Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)